Overt signs of toxicity in rats administered the technical were fairly non-specific and included weakness, dis-orientation, rough coat, decreased movement, flaccidity, exophthalmus, lacrimation and respiratory disturbances. In rats administered the 100SL formulation, there were no overt signs of toxicity during the 14-day observation period. At post mortem there were no gross histological effects in the studies with the technical and formulated product.
Clinical signs of toxicity in mice administered the technical or the 100SL formulation were staggering gait, decreased spontaneous movement, deep breathing, tonic convulsions or prone position and oligopnea. At post mortem dark red patches in the grandular stomach were observed in more than half of the mice administered technical or 100SL formulation, and dark reddening of the lungs were observed in a few mice administered 100SL formulation.
No signs of systemic toxicity were observed in the rat administered dermally the technical and the 100SL formulation. In the inhalation toxicity study in the rat, slight sedation, dyspnoea and ruffled fur were observed during and after exposure oftechnical in all animals but resolved within 24 hr.
IRRITATION STUDIES l. Primary Eye Irritation
Six New Zealand White rabbits were used in each cyproconazole technical or 100SL formulation study. A 0.06 g of the technical or 0.1 ml of the 100SL formulation was placed into the lower everted lid of one eye of each animal. The eyelids were then gently held together for one second before releasing. The contralateral eye remained untreated and served as a control. Examination of the eyes was made after 1 hr and 1, 2, 3, 4, 7 days after instillation.
Instillation of cyproconazole technical or its 100SL formulation resulted in conjunctival reaction only in all 6 animals. The eyes were normal 3 days after instillation. Based on the result, cyproconazole technical and lOOSL formulation are slight eye irritants.
(Huntingdon Research Centre Ltd., 1988 Ltd., , 1989 
Primary Skin Irritation
Six New Zealand White rabbits were used in each cyproconazole technical or 100SL formulation study. A 0.5 g of the technical was applied under a 2.5 cm square gauze moistened with 0.5 ml distilled water to one intact skin site on each animal. In the case of 100SL formulation, 0.5 ml of the formulation was applied under the same experimental conditions as in the technical study. After 4 hr the bandages were removed and the application sites were washed. Observations were made on day 1 (i.e. 30 min after removal the bandages) and days 2, 3, 4.
Following removal of the bandages after application of cyproconazole technical or its 100SL formulation, no evidence of erythema or oedema could be found. None of the animals showed any observable response to treatment during the following 3 days. Based on the result, cyproconazole and 100SL formulation are not skin irritants. (Huntingdon Research Centre Ltd., 1988 , 1989 DERMAL SENSITIZATION STUDIES The Maximization method was employed for a dermal sensitization study. Cyproconazole technical or its 100SL formulation was applied to 20 guinea pigs. A negative control group of 20 animals and a positive control, 1-chloro-2, 4-dinitrobenzene (DNCB), group of 20 animals were provided.
Following challenge application of cyproconazole technical or its 100SL formulation, no dermal reactions were observed in any of the test or control animals. According to these results, cyproconazole technical and its 100SL formulation were considered to be not a skin-sensitizer.
In addition the positive control, DNCB, produced evidence of delayed contact hypersensitivity in both studies. (Sandoz Ltd., 1985 , 1986 SUBCHRONIC TOXICITY STUDIES
13-Week Feeding Study in Rats
A main group of each 15 male and 15 female Han Wistar rats per dose level was given diet containing cyproconazole technical at concentration of 0, 20, 80 or 320 ppm for 13 weeks. In a parallel study 15 animals of each sex were given diet containing cyproconazole technical at concentration of 0 or 320 ppm for 13 weeks followed by a 4-week recovery period.
All animals survived until termination of the study. The only overt sign of toxicity was piloerection in male rats receiving 80 or 320 ppm. Body weight was not affected except for a significant decrease in female rats at 320 ppm. Food consumption was not affected by the treatment except the consumption of satellite male rats at 320 ppm was reduced in the first week. There were no treatment related changes in haematology or urinalysis values. The clinical biochemistry parameters were not affected by the treatment except aspartate aminotransferase activity in female rats at 80 or 320 ppm which was increased in the last week of the study.
In post mortem examination, liver weights in both sexes receiving 320 ppm were increased but not in those of the recovery group. Histopathological examination revealed vacuolated hepatocytes, predominantly centrilobular, in male rats at 320 ppm. Individualization of hepatocytes lobular distinct pattern occurred in both sexes at 320 ppm. These hepatic effects were reversible, they were not found in the recovery group.
Based on the result of this study, the no observed effect level was 20 ppm (male 1.5, female 1.9 mg/kg/day).
(Sandoz Ltd., 1986)
13-Week Feeding Study in Dogs
Groups of 4 male and 4 female Beagle dogs were fed diets containing cyproconazole technical at concentration of 0, 20, 100 or 500 ppm for 13 weeks.
All animals survived until termination of the study. Apart from reduced muscle tone and subdued behavior in male and female dogs at 500 ppm, no other overt sign of toxicity were observed. Body weight gain in male dogs and female dogs receiving 500 ppm was slightly reduced and food consumption in male dogs receiving 500 ppm was reduced.
Cyproconazole affected clinical biochemistry parameters in animals receiving 500 and 100 ppm. Dogs receiving 500 ppm, creatinine levels, alkaline phosphatase activity, gamma-glutamyl transferase activity and glutamate dehydrogenase activity were significantly increased in both sexes, triglycerides levels, albumin levels, calcium levels and inorganic phosphate levels were significantly decreased in both sexes, total-cholesterol and high density lipoprotein-cholesterol levels were significantly reduced in male dogs. Because of the reduction in muscle tone seen in animals receiving 500 ppm, creatinine phosphokinase levels were measured and found to be elevated in male dogs receiving 500 ppm. Total protein levels were significantly decreased in female dogs receiving 500 ppm. Animals receiving 100 ppm, creatinine levels were increased in both sexes, gamma-glutamyl transferase activity was increased in female dogs. There were no treatment related effects in urinalysis values.
Post mortem examination revealed significantly increased liver weights in both sexes at 500 ppm and a slight increase in male dogs at 100 ppm. Histopathological examination showed centrilobular hepatocyte hypertrophy in both sexes receiving 500 or 100 ppm.
Based on the result of this study, the no observed effect level was 20 ppm (male 0.77, female 0.70 mg/kg/day).
CHRONIC TOXICITY AND ONCOGENICITY STUDIES 1. Combined Chronic Toxicity/Oncogenicity Study in Rats
Seventy male and 70 female Wistar rats were fed diets containing cyproconazole technical at concentration of 0, 20, 50 or 350 ppm for 118 and 121 weeks, respectively. Approximately 60% of the animals, including 72% (male) and 64% (female) of the control, died or were killed in extremis before the end of the study. These effects were not treatment related. There were no overt signs of toxicity and opthalmoscopy revealed no treatment related findings. Body weight gain was significantly reduced in both sexes at 350 ppm. Food consumption was not affected by treatment except the food efficiency in male rats at 350 ppm was reduced.
Laboratory investigations were performed at 14, 26, 52, 78, 105 weeks and at termination. Haemoglobin values in females rats at 50 or 350 ppm were significantly reduced. Alanine aminotransferase and aspartate aminotransferase activities in male rats receiving 350 ppm were significantly increased. Total cholesterol, total protein and globulin levels in female rats at 50 or 350 ppm were increased. Gamma-glutamyl transferase activity in both sexes at 50 or 350 ppm were increased, but did not achieve statistical significance at any sampling period. The other parameters of clinical biochemistry were not affected by treatment. There were no treatment related effects in urinalysis values.
Post mortem examination revealed significantly increased liver weights in both sexes at 350 ppm. In histopathological examination hepatocellular fatty changes in male rats at 350 ppm and hepatocellular hypertrophy in female rats at 350 ppm were found as treatment related effects. Lipoproteinosis in lung was found in male rats at 350 ppm. The incidence of neoplastic lesions was not affected by the treatment at the terminal or interim sacrifice.
Based on the above mentioned result, the no effect levels for this study was 20 ppm (male 1.0, female 1.2 mg/kg/day).
(Sandoz Ltd., 1988)
Oncogenicity Study in Mice
Groups of 50 male and 50 female ICR mice were given cyproconazole technical at concentration of 0, 5, 15, 100 or 200 ppm in the diet for 81 and 88 weeks respectively.
Mortalities of control, 5, 15, 100 and 200 ppm groups were 65, 60, 50, 42 and 28% respectively in male rats and 60, 52, 60, 28 and 46% respectively in female rats. There were no overt signs of toxicity. Food consumption was not affected by treatment although reduced body weight gains were found in both sexes at 100 and 200 ppm. Blood smears drawn after 52, 79 weeks and prior to female terminal sacrifice (90 weeks) from mice were evaluated for differential white blood cell count. White blood counts at interim sacrifice or terminal investigation were not affected by treatment.
At post mortem liver weight were significantly increased in both sexes receiving 100 or 200 ppm. In macroscopic examination an increased incidence of liver nodules was found among male and female rats treated with 100 or 200 ppm. In histopathological examination single-cell hepatocytic necrosis and diffuse hepatocytic hypertrophy were found in male rats at 100 or 200 ppm and in female rats at 200 ppm. Other changes that were associated with treatment included testicular germinal epithelial deficit and possibly an increase in skin wounds in male rats at 200 ppm. An incidence of hepatocytic neoplasia was increased in males rats at 100 or 200 ppm and in females at 200 ppm. The mechanism leading to the observed hepatocytic neoplasia is tumour promotion as a result of hepatic enzyme induction, a non-genotoxlc event. This mechanism was supported by a "Cell proliferation study" and an "Enzyme induction study." Additionally, it should also be noted that a comprehensive array of tests, both in vivo and in vitro, with and without metabolic activation, did not show any genotoxic activity of cyproconazole.
Based on the above mentioned result, the no effect levels for this study was 15 ppm (male 1.84, female 2.56 mg/kg/day). (Sandoz Ltd., 1989) 
Chronic Toxicity Study in Dogs
Groups of 4 male and 4 female beagle dogs were fed diets containing cyproconazole at concentration of 0, 30, 100 or 350 ppm for 52 weeks. All animals survived until the end of the study. Female dogs of the 100 and 350 ppm treatment groups showed subdued behavior for 4 and 1 week respectively, otherwise there were no overt signs of toxicity. Ophthalmoscopy revealed no treatment related effects. Body weight gain in male dogs at 350 ppm was slightly reduced in the first 9 weeks. Food consumption was not affected by treatment in both sexes. Blood samples were obtained from all dogs before commencement of treatment. During the treatment period, blood samples were obtained at 13, 26, 38 weeks and prior to termination. Laboratory investigation showed elevated platelet counts in both sexes at 100 or 350 ppm. However, prothrombin time at the same dose were not affected by treatment. Cholesterol and albumin levels were reduced in both sexes at 350 ppm, total protein was reduced in male dogs at 350 ppm. Alkaline phosphatase activity and percentage globulin were increased in both sexes at 350 ppm, alanine aminotransferase activity was increased only in male dogs at 350 ppm. Cytochrome P-450 activities were increased in both sexes at 350 ppm and in female dogs at 100 ppm. Urinalysis revealed no dose related effects.
At post mortem examination, liver weights of both sexes at 350 ppm were significantly increased. In macroscopic examination, the livers of 2 male dogs at 350 ppm appeared enlarged with pronounced lobular patterning. In histopathological examination, treatment-related lesions were confined to the liver. Laminar eosinophilic intrahepatocytic bodies were present in all male dogs at 350 ppm and in one male dog at 100 ppm. They were also present in 2 female dogs at 350 ppm.
Based on the above mentioned result, the no effect levels for this study was 30 ppm (male, female 0.99 mg/kg/day).
REPRODUCTION AND TERATOLOGY STUDIES l. 2-Generation Reproductive Study in Rats
In a 2-generation study groups of Wistar rats were fed diets containing cyproconazole technical at concentration of 0, 4, 20 or 120 ppm and the effect of treatment on the reproductive function was assessed. One litter per generation was produced, 26 animals of each sex of the F0 and F1 generation were used in the study. The test material was administered to the parental F0 during the premating (10 weeks), mating, the resulting pregnancy and through weaning of their offspring. The F1 parents were treated in the same way except the premating period which covered a period of 12 weeks.
There were no overt sign of toxicity and no treatment related deaths. Body weight gain and food consumption were not affected by treatment in both sexes and both generations. There were no effect of treatment on the reproductive function of the two generations.
At post mortem, histopathological examination revealed increased hepatocellular fatty changes in the F0 males at 120 ppm. No treatment related changes were seen in the F1 or F2 pups on histopathological examination.
Based on the above mentioned result, the no effect level in males was 20 ppm and that in females was 120 ppm (male 1.39, female 9.88 mg/kg/day).
(Sandoz Ltd., 1987)
Teratology Study in Rats
Groups of 25 pregnant female Wistar rats were dosed cyproconazole technical orally at dose levels of 0, 6, 12, 24 or 48 mg/kg/day on days 6-15 of pregnancy. Distilled water containing 4% carboxymethyl cellulose sodium salt was used as the vehicle.
There were no overt signs of toxicity. Body weight gain was reduced during from first to third treatment days in female rats at 48 mg/kg/day and from day 12 post coitum to day 21 post coitum in female rats at 24 mg/kg/day. Food consumption was reduced during treatment in females receiving 24 or 48 mg/kg/day. A dose-related, significantly increased postimplantation loss in females at 24 or 48 mg/kg/day was observed. The significantly reduced body weights of fetuses at 24 or 48 mg/kg/day as well as the effects on skeletal development were considered to be caused by the primary maternal toxicity. A hydrocephalus and palatoschisis were observed in fetuses at 48 mg/kg/day. Based on the above mentioned result, the no effect level was 12 mg/kg/day (maternal and embryo/teratogenicity). (Research & Consulting Company AG, 1986) 
Teratology Study in Rabbits
Groups of 16 females Chinchilla rabbits were dosed cyproconazole technical by orally at dose level of 0, 2, 10 or 50 mg/kg/day on days 6-18 of pregnancy. Distilled water containing 4% carboxymethyl cellulose sodium salt was used as the vehicle.
There were no overt signs of toxicity. Body weight gain and food consumption were reduced in females at 50 mg/kg/day. Pre-implantation loss was not affected by treatment however postirnplantation losses were significantly increased at 50 mg/kg/day. Examination for external, skeletal and visceral abnormalities revealed no treatment related effects.
Based on the above mentioned result, the no effect level was 10 mg/kg/day (maternal and embryo/teratogenicity).
(Research & Consulting Company AG, 1986)
MUTAGENICITY STUDIES 1. Reverse Mutation Assay
Five strains of Salmonella typhimurium, TA 1535, TA 1537, TA 1538, TA 98 and TA 100 and Escherchia coli WP2 uvrA were used to evaluate the mutagenic potential of cyproconazole technical. The study of 5 strains of S. typhimurium was carried out at a dose level of 0, 1, 5, 10, 100, 500, 1000, 2500 and 5000 µg per plate of cyproconazole with or without metabolic activation. The study of E.coli WP2 uvrA was carried out at dose level of 0, 31.3, 62.5, 125, 250, 500, 1000 and 2000 µg per plate of cyproconazole with or without metabolic activation.
Cyproconazole induced no appreciable increases in the number of revertant colonies of any strain at any dose with or without metabolic activation, compared with those of the corresponding control. Based on the result, cyproconazole was not considered to have capability of inducing reverse mutation.
(Hazleton Biotechnologies, 1986) (The Institute of Environmental Toxicology, 1992) 
